National Science Foundation RII Track-1 Project:Expanding Research, Education and Innovation in South Dakota
SD EPSCoR News
Mechanism of Action of first in class Fully Human Anti-ThymoGlobulin experimental Drug (SAB-142) as a Treatment Option for Type 1 Diabetes — 11a — Olivia Allen, Quincee Simonson
Sanford Research
Alexei Savinov
Mechanism of Action of first in class Fully Human Anti-ThymoGlobulin experimental Drug (SAB-142) as a Treatment Option for Type 1 Diabetes — 11a — Olivia Allen, Quincee Simonson
Sanford Research
Alexei Savinov